Repare Therapeutics
Biotechnology ResearchView the employees at
Repare Therapeutics-
Elliot Goodfellow, PhD Postdoctoral Research Fellow Skilled in Chemical and Biological Disciplines
-
Canada
-
Top 5%
Christopher Fiore Associate Director, Bioinformatics at Repare Therapeutics-
Top 5%
Jesse Leblanc Research Scientist III at Repare Therapeutics-
Rising Star
Riley Thompson Document Control Specialist at Repare Therapeutics-
New York, New York, United States
-
Rising Star
Lloyd Mitchell Segal CEO at Repare Therapeutics (Nasdaq: RPTX)-
Montreal, Quebec, Canada
-
Top 5%
Overview
Repare Therapeutics (Nasdaq: RPTX) is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit www.reparerx.com.
-